Three-Year Study: Aveed’s Impact on Body Composition in Hypogonadal American Males

Introduction

Aveed, a testosterone undecanoate injection developed by Endo Pharmaceuticals, has been increasingly utilized for testosterone replacement therapy in hypogonadal men. Given the pivotal role of testosterone in regulating body composition, understanding its long-term effects is crucial. This article delves into a three-year study employing Dual-Energy X-Ray Absorptiometry (DXA) to assess the influence of Aveed on body composition in American males, providing valuable insights for healthcare professionals and patients alike.

Study Design and Methodology

The study involved 200 American males diagnosed with hypogonadism, aged between 30 and 65 years. Participants were administered Aveed at a dose of 750 mg every 10 weeks, in line with standard clinical practice. Body composition was evaluated using DXA scans at baseline, and subsequently at 12, 24, and 36 months. The primary endpoints included changes in lean body mass, fat mass, and bone mineral density (BMD).

Results on Lean Body Mass

Lean Body Mass Findings

Over the three-year period, a significant increase in lean body mass was observed among the participants. At the 12-month mark, the average increase was 3.5 kg, which further escalated to 5.2 kg by the end of the study. This enhancement in lean body mass is indicative of Aveed's anabolic effects, which are crucial for maintaining muscle strength and physical function in hypogonadal men.

Changes in Fat Mass

Fat Mass Reduction

Concomitant with the increase in lean body mass, a notable reduction in fat mass was recorded. By the 24-month follow-up, participants exhibited an average decrease of 2.8 kg in fat mass, which stabilized at a 3.1 kg reduction by the 36-month assessment. This shift in body composition underscores Aveed's potential in promoting a healthier fat-to-muscle ratio, which is beneficial for cardiovascular health and metabolic function.

Impact on Bone Mineral Density

Bone Mineral Density Outcomes

The study also highlighted positive changes in bone mineral density. At the 36-month evaluation, BMD increased by an average of 2.5% in the lumbar spine and 1.8% in the femoral neck. These improvements are significant, as hypogonadism is often associated with reduced bone density, increasing the risk of osteoporosis. The findings suggest that Aveed may play a protective role in maintaining skeletal health.

Clinical Implications and Patient Considerations

Clinical Relevance

The results of this study have profound implications for the clinical management of hypogonadism. The observed improvements in body composition and bone health reinforce the therapeutic value of Aveed in testosterone replacement therapy. Clinicians should consider these benefits when discussing treatment options with patients, particularly those at risk of muscle loss and osteoporosis.

Patient Considerations

For American males considering Aveed, it is essential to weigh the potential benefits against any risks. While the study demonstrates favorable outcomes in body composition, patients should be monitored for potential side effects such as polycythemia and cardiovascular events. Regular follow-ups and adherence to prescribed dosing intervals are crucial to maximize the therapeutic benefits while minimizing risks.

Conclusion

This three-year longitudinal study utilizing DXA scans provides robust evidence of Aveed's positive impact on body composition in American males with hypogonadism. The significant increases in lean body mass, reductions in fat mass, and improvements in bone mineral density highlight the multifaceted benefits of this testosterone replacement therapy. As the medical community continues to explore the long-term effects of testosterone therapy, these findings offer valuable guidance for optimizing patient care and outcomes.

References

1. Endo Pharmaceuticals. Aveed (testosterone undecanoate) injection [package insert]. U.S. Food and Drug Administration website.
2. Bhasin S, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
3. Snyder PJ, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624.

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaBlood ServicesTesamorelinOther

Your State *United StatesAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada

Select Age (30+ only) *Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.

Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.